We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

104 hedge funds and large institutions have $657M invested in Lexicon Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

5% more funds holding

Funds holding: 99 → 104 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

12% less capital invested

Capital invested by funds: $749M → $657M (-$92.3M)

16% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 32

Holders
104
Holders Change
+5
Holders Change %
+5.05%
% of All Funds
3.02%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
12
Increased
27
Reduced
32
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UBS AM
UBS AM
Illinois
+$6.1M
2
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Kentucky
+$778K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$186K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$167K
5
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
+$131K

Top Sellers

1
Norges Bank
Norges Bank
Norway
-$3.87M
2
Axa
Axa
France
-$725K
3
Deutsche Bank
Deutsche Bank
Germany
-$380K
4
TA
Teton Advisors
New York
-$302K
5
Bank of America
Bank of America
North Carolina
-$260K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
51
Goldman Sachs
New York
$121K +$1.75K +164 +1%
MAA
52
Managed Account Advisors
New Jersey
$114K +$51.9K +4,859 +73%
TRCT
53
Tower Research Capital (TRC)
New York
$100K +$108K +10,099 New
N
54
Nuveen
North Carolina
$78K – – –
OL
55
Orbitronix LP
California
$71K +$76.3K +7,143 New
Commonwealth Equity Services
56
Commonwealth Equity Services
Massachusetts
$69K – – –
Public Employees Retirement Association of Colorado
57
Public Employees Retirement Association of Colorado
Colorado
$67K – – –
Legal & General Group
58
Legal & General Group
United Kingdom
$66K +$71.1K +6,655 New
U
59
UBS
Switzerland
$65K -$6.35K -595 -8%
Barclays
60
Barclays
United Kingdom
$63K -$93.1K -8,717 -49%
RG
61
Rathbones Group
United Kingdom
$62K – – –
TA
62
Teton Advisors
New York
$52K -$302K -28,285 -84%
M&T Bank
63
M&T Bank
New York
$49K +$53.8K +5,034 New
CNB
64
City National Bank
California
$48K -$3.63K -340 -7%
Tudor Investment Corp
65
Tudor Investment Corp
Connecticut
$41K +$6.99K +655 +19%
Citigroup
66
Citigroup
New York
$40K -$3.02K -283 -7%
Creative Planning
67
Creative Planning
Kansas
$38K +$22.9K +2,143 +122%
AB
68
Amalgamated Bank
New York
$29K +$117 +11 +0.4%
Prudential Financial
69
Prudential Financial
New Jersey
$26K -$27.2K -2,543 -49%
Los Angeles Capital Management
70
Los Angeles Capital Management
California
$26K -$3.14K -294 -10%
CIBC Asset Management
71
CIBC Asset Management
Ontario, Canada
$26K – – –
AIP
72
Ameritas Investment Partners
Nebraska
$25K – – –
GC
73
Guggenheim Capital
Illinois
$24K -$2.69K -252 -9%
Comerica Bank
74
Comerica Bank
Texas
$24K +$3K +281 +13%
Wells Fargo
75
Wells Fargo
California
$21K -$11.6K -1,090 -34%
1 2
3
4 5

LXRX Hedge Fund Activity: Q3 2014 in Review

104 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2014, worth a combined $657M — down 12% from $749M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new LXRX positions and 7 closed out — a net gain of 5 holders — while 27 added to existing stakes and 32 trimmed.

The largest buyer was UBS AM, adding an estimated $6.1M. The largest seller was Norges Bank, cutting an estimated $3.87M.

  • 104 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2014, up from 99 in Q2 2014.
  • Funds reported $657M of Lexicon Pharmaceuticals stock for Q3 2014, down 12% quarter-over-quarter.
  • 12 funds opened new Lexicon Pharmaceuticals positions in Q3 2014 and 7 closed out, a net change of +5 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q3 2014 was UBS AM, an estimated $6.1M added.
  • The largest Lexicon Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $3.87M sold.

Based on aggregated 13F filings for Q3 2014.